Terrence Flynn, a Morgan Stanley analyst, discusses the burgeoning market for obesity medications, specifically GLP-1 medicines. He projects the global market to reach $150 billion by 2035, driven by increased production, broader clinical applications (treating conditions beyond obesity), expanding healthcare coverage, the development of pill forms, and next-generation medications. He highlights the current low adoption rates and anticipates a significant surge, impacting various sectors beyond biopharma, including medical technology, healthcare services, and consumer markets like food and fashion.
Outlines
Sign in to continue reading, translating and more.
Open full episode in Podwise